Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight
Sponsor: Eli Lilly and Company
Summary
The main purpose of this study is to see how much of orforglipron (study drug) gets into the bloodstream and how long it takes the body to get rid of it when given as capsules compared to tablets in healthy overweight and obese participants. The safety and tolerability (side effects) of orforglipron when given as capsules and tablets will also be evaluated. The study will be conducted in two parts, with part A and B lasting up to approximately 25 and 22 weeks each respectively, including the screening period.
Official title: A Multiple-Dose Study to Investigate the Bioequivalence of Orforglipron (LY3502970) Capsules and Orforglipron Tablets in Participants With Obesity or Overweight Who Are Otherwise Healthy.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
533
Start Date
2024-06-24
Completion Date
2025-06-02
Last Updated
2026-07-17
Healthy Volunteers
Yes
Conditions
Interventions
Orforglipron
Administered orally
Locations (7)
Anaheim Clinical Trials, LLC
Anaheim, California, United States
Collaborative Neuroscience Research, LLC
Los Alamitos, California, United States
Fortrea Clinical Research Unit
Daytona Beach, Florida, United States
Altasciences Company Inc.
Overland Park, Kansas, United States
QPS
Springfield, Missouri, United States
Fortrea Clinical Research Unit
Dallas, Texas, United States
Fortrea Clinical Research Unit
Madison, Wisconsin, United States